Olema Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Olema Pharmaceuticals, Inc. (OLMA) on April 27, 2026. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel and governance matters.
Material Changes
On April 27, 2026, the Board of Directors appointed Dr. Prakash Raman as a Class II director, effective April 28, 2026. His term will expire at the 2028 annual meeting of stockholders. The Board determined Dr. Raman qualifies as an independent director under Nasdaq Rules.
Compensatory Arrangements
In connection with his appointment, Dr. Raman received the following equity awards under the Company's 2020 Equity Incentive Plan:
- Initial Grant: Nonstatutory stock option to purchase 24,150 shares, vesting in 36 equal monthly installments over three years.
- Partial Year Grant: Nonstatutory stock option to purchase 2,911 shares, vesting in full on June 11, 2026.
The Company also entered into a standard indemnification agreement with Dr. Raman. No other transactions requiring disclosure under Item 404(a) of Regulation S-K exist.
Outlook and Risks
The filing contains no management commentary regarding business outlook, risks, contingencies, or unusual items. A press release announcing the appointment was issued on April 29, 2026, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify Dr. Prakash Raman's professional background and independence status.
- Review the terms of the 2020 Equity Incentive Plan regarding director compensation.
- Confirm the total number of outstanding shares and the impact of the new option grants on dilution.
- Check for any subsequent filings regarding the vesting schedule or changes to the Board composition.